Cabazitaxel is a semi-synthetic taxoid that is an effective antineplastic agent used in the treatment of prostate cancer and breast cancer. Cabazitaxel is shown to disrupt the microtubular network in cells that exhibit P-glycoprotein (Pgp) mediated drug resistance. Its poor affinity for Pgp makes it a more effective therapeutic agent than docetaxel in cancer cells that become resistant to taxane class of cancer drugs.
| Cas No. | 183133-96-2 |
|---|---|
| Purity | ≥98% |
| Formula | C45H57NO14 |
| Formula Wt. | 835.94 |
| Chemical Name | 1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-ene-2,4,13-triyl 4-acetate 2-benzoate 13-((2R,3S)-3-(((tertbutoxy)carbonyl)amino)-2-hydroxy-3-phenylpropanoate) |
| IUPAC Name | (2α,5β,7β,10β,13α)-4-Acetoxy-1-hydroxy-13-{[(2R,3S)-2-hydroxy-3-({[(2-methyl-2-propanyl)oxy]carbonyl}amino)-3-phenylpropanoyl]oxy}-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate |
| Synonym | XPR-6258; TXD 258; Taxoid XRP6258; RPR 116258A, jevtana. |
| Solubility | Soluble in DMSO (~100 mg/mL), ethanol (~50 mg/mL). Sparingly soluble in water. |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | C002041 Info Sheet PDF |
|---|
